US20010007664A1 - Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process - Google Patents

Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process Download PDF

Info

Publication number
US20010007664A1
US20010007664A1 US09/000,389 US38998A US2001007664A1 US 20010007664 A1 US20010007664 A1 US 20010007664A1 US 38998 A US38998 A US 38998A US 2001007664 A1 US2001007664 A1 US 2001007664A1
Authority
US
United States
Prior art keywords
lipids
melt
production
melt extrusion
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/000,389
Other versions
US6387401B2 (en
Inventor
Joerg Rosenberg
Jorg Breitenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
AbbVie Deutschland GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to BASF AKTIENGESELLSCHAFT reassignment BASF AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BREITENBACH, JOERG, ROSENBERG, JOERG
Publication of US20010007664A1 publication Critical patent/US20010007664A1/en
Application granted granted Critical
Publication of US6387401B2 publication Critical patent/US6387401B2/en
Assigned to ABBVIE DEUTSCHLAND GMBH & CO KG reassignment ABBVIE DEUTSCHLAND GMBH & CO KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABBOTT GMBH & CO KG
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention relates to the use of lipids as aids in the production of solid drug forms by melt extrusion.
  • Known mold release agents for conventional processes are, for example, fatty acid esters or fatty acid salts, with only magnesium stearate normally being used in practice. Magnesium stearate is normally added to the granules which contain active ingredient and are ready before tabletting.
  • melt-processable cellulose derivatives such as hydroxypropylcellulose are, as water-soluble polymers, very suitable for producing tablets by solvent-free melt extrusion/calendering. It is possible by admixture of other ancillary substances, eg. HPMC (hydroxypropylmethylcellulose) polymers which are swellable in water, to control the dissolution times of such tablets in the gastrointestinal tract, as is disclosed, for example, in DE-A 4226753.
  • HPMC hydroxypropylmethylcellulose
  • the lipids which are suitable according to the invention are mono-, di- and triglycerides of naturally occurring fatty acids, for example glycerol monostearate, glycerol distearate, glycerol tristearate, glycerol tripalmitate, glycerol trimyristate, glycerol tribehenate, glycerol palmitate stearate or glyceride mixtures occurring in natural oils, preferably hydrogenated castor oil.
  • naturally occurring fatty acids for example glycerol monostearate, glycerol distearate, glycerol tristearate, glycerol tripalmitate, glycerol trimyristate, glycerol tribehenate, glycerol palmitate stearate or glyceride mixtures occurring in natural oils, preferably hydrogenated castor oil.
  • Ceramides are furthermore also suitable for this purpose.
  • Preferred lipids are, in particular, phospholipids, with phosphoglycerides such as lecithins being particularly preferred. Hydrogenated lecithins such as soybean and egg lecithins are very particularly preferred.
  • the lipids can be used in amounts of 0.1- 10%, preferably 1-5%, of the total weight of the preparations containing active ingredient.
  • compositions containing active ingredient can contain as matrix polymers melt-processable polymers, for example
  • carboxyalkylcelluloses such as carboxymethylcelluloses, alkylcelluloses such as methylcellulose,
  • hydroxyalkylcelluloses such as hydroxymethyl-, hydroxyethyl-, hydroxypropyl- and hydroxybutylcellulose
  • hydroxyalkylcelluloses such as hydroxyethylmethyl- and hydroxypropylmethylcellulose, or mixtures thereof.
  • Preferred polymers are hydroxypropylcelluloses and polymers based on vinylpyrrolidone.
  • Suitable active ingredients are all active ingredients which do not decompose under the conditions of melt extrusion.
  • the amount of the active component in the complete preparation can vary within wide limits depending on the activity and release rate.
  • the content of active ingredient can be in the range from 0.1 to 90%, preferably from 0.5 to 60%, of the total weight of the preparation. The only condition is that the preparation is still melt-processable.
  • the preparations may furthermore contain conventional pharmaceutical ancillary substances such as bulking agents, colorants, disintegrants or stabilizers in conventional amounts.
  • the components are processed in a conventional way in extruders, preferably in single or twin screw extruders at a temperature in the range from 50 to 200° C.
  • the shaping of the polymer melt which contains active ingredient and is free of solvent to give the preparations according to the invention can take place, for example, by calendering the extrudate and by converting the extrudate with rotating knives into pellets which have identical volumes and have a solidified surface but are still moldable, and subsequently compressing to tablets in conventional tabletting machines.

Abstract

Lipids are used as aids in the production of solid drug forms by melt extrusion.

Description

  • The present invention relates to the use of lipids as aids in the production of solid drug forms by melt extrusion. [0001]
  • The production of solid drug forms by melt extrusion is disclosed, for example, in U.S. Pat. No. 4,880,585, wherein the drug form is produced from the melt, which contains active ingredient and is still plastic, with the aid of a molding calender which directly molds tablets from the melt. [0002]
  • It has long been known that, in almost all cases when tablets are made from granules, satisfactory results are achieved only if a small amount of a lubricant is added to the formulations, after the granulation but before the tabletting, and this is deposited as a fine film on the outsides of the granule particles and thus prevents adhesion of the granules to the tabletting punches. The effect of these lubricants is very great although it is necessary to add only very small amounts to the granules (generally about 0.1 to 1% by weight; cf. H. Sucker, P. Fuchs. P. Speiser: Pharmazeutische Technologie; Georg Thieme Verlag, Stuttgart (1991), pages 259-260). [0003]
  • Known mold release agents for conventional processes are, for example, fatty acid esters or fatty acid salts, with only magnesium stearate normally being used in practice. Magnesium stearate is normally added to the granules which contain active ingredient and are ready before tabletting. [0004]
  • In the production of drug forms by melt extrusion in conjunction with a tabletting process such as calendering, it is crucial that the melt does not adhere to the surfaces of the calender rolls because, otherwise, there is no release from the molds. It also has to be taken into account in calendering to produce tablets that the compression process in the calender results in tablets which have a typical fin which is formed at the interface of the pairs of molding rolls which are in contact only at the surface. Following the calendering, this fin must be removed mechanically, generally after cooling/hardening of the melt tablets, in order to provide the tablets with a homogeneous surface structure. The success of this deflashing depends crucially on the consistency of the cooled melt containing active ingredient. This means that despite the calendering being satisfactory (no adhesion of the melt in the calender), deflashing of the resulting tablets is not necessarily possible. Many polymers form thermoplastic melts even in the presence of large amounts of active ingredients and/or ancillary substances, and these are highly flexible after cooling and can be flexed over wide ranges without breakage. In these cases, removal of the fins is very difficult and often completely impossible, although there are no problems with the extrusion and the calendering too. [0005]
  • Thus, it is crucial for the use of a formulation for producing tablets by melt extrusion/calendering that, besides the complete mixture having good thermoplasticity, in particular it is also possible to reduce the tendency to adhere during the calendering and control the plasticity of the cooled melt in order to ensure deflashing of the tablets. [0006]
  • Melt-processable cellulose derivatives such as hydroxypropylcellulose are, as water-soluble polymers, very suitable for producing tablets by solvent-free melt extrusion/calendering. It is possible by admixture of other ancillary substances, eg. HPMC (hydroxypropylmethylcellulose) polymers which are swellable in water, to control the dissolution times of such tablets in the gastrointestinal tract, as is disclosed, for example, in DE-A 4226753. [0007]
  • However, it has now been found that, in many cases when hydroxypropylcelluloses are used as water-soluble, thermoplastic polymer component, although the resulting melts can be extruded satisfactorily, they [0008]
  • (a) in many cases showed an extreme tendency to adhere during the calendering, [0009]
  • (b) did not permit removal of the fin because of excessive plasticity of the cooled melts (containing active ingredient) in the case of the calendered tablets, and [0010]
  • (c) caused considerable problems in cleaning the extruders because of the great tendency of the melt to adhere. [0011]
  • It is an object of the present invention to find aids which make it possible, especially when hydroxypropylcelluloses are used as matrix polymers in the production of drug forms by melt extrusion, to solve the abovementioned problems. [0012]
  • We have found that this object is achieved by using lipids as mold release agents and lubricants in the production of drug forms by melt extrusion. [0013]
  • The lipids which are suitable according to the invention are mono-, di- and triglycerides of naturally occurring fatty acids, for example glycerol monostearate, glycerol distearate, glycerol tristearate, glycerol tripalmitate, glycerol trimyristate, glycerol tribehenate, glycerol palmitate stearate or glyceride mixtures occurring in natural oils, preferably hydrogenated castor oil. [0014]
  • Ceramides are furthermore also suitable for this purpose. [0015]
  • Preferred lipids are, in particular, phospholipids, with phosphoglycerides such as lecithins being particularly preferred. Hydrogenated lecithins such as soybean and egg lecithins are very particularly preferred. [0016]
  • The lipids can be used in amounts of 0.1- 10%, preferably 1-5%, of the total weight of the preparations containing active ingredient. [0017]
  • The preparations containing active ingredient can contain as matrix polymers melt-processable polymers, for example [0018]
  • polyvinylpyrrolidone, [0019]
  • copolymers of N-vinylpyrrolidone and vinyl acetate with up to 50% by weight of vinyl acetate, [0020]
  • carboxyalkylcelluloses such as carboxymethylcelluloses, alkylcelluloses such as methylcellulose, [0021]
  • hydroxyalkylcelluloses such as hydroxymethyl-, hydroxyethyl-, hydroxypropyl- and hydroxybutylcellulose, [0022]
  • hydroxyalkylcelluloses such as hydroxyethylmethyl- and hydroxypropylmethylcellulose, or mixtures thereof. [0023]
  • Preferred polymers are hydroxypropylcelluloses and polymers based on vinylpyrrolidone. [0024]
  • Suitable active ingredients are all active ingredients which do not decompose under the conditions of melt extrusion. [0025]
  • The amount of the active component in the complete preparation can vary within wide limits depending on the activity and release rate. Thus, the content of active ingredient can be in the range from 0.1 to 90%, preferably from 0.5 to 60%, of the total weight of the preparation. The only condition is that the preparation is still melt-processable. [0026]
  • The preparations may furthermore contain conventional pharmaceutical ancillary substances such as bulking agents, colorants, disintegrants or stabilizers in conventional amounts. [0027]
  • Otherwise, the components are processed in a conventional way in extruders, preferably in single or twin screw extruders at a temperature in the range from 50 to 200° C. The shaping of the polymer melt which contains active ingredient and is free of solvent to give the preparations according to the invention can take place, for example, by calendering the extrudate and by converting the extrudate with rotating knives into pellets which have identical volumes and have a solidified surface but are still moldable, and subsequently compressing to tablets in conventional tabletting machines. [0028]
  • It is possible to mix the ancillary substances into the melt or solution of active ingredients and polymers. It is furthermore possible to incorporate the ancillary substances together with the active ingredient into the polymer melt. In addition, mixtures of ancillary substances, the active ingredient and the polymers can be directly melted. It is generally customary for a physical mixture of ancillary substances, active ingredients and the polymers to be melted together. [0029]
  • It has been found, surprisingly, that addition of even small amounts of lipids is able to prevent adhesion of the melts containing active ingredient. [0030]
  • Addition of only 3% by weight of lecithin reduces the melt adhesion of the extruded composition so much that the formulations can be calendered without restrictions. The cleaning of the extruder to remove the otherwise viscous, highly adhesive melt residues is considerably simplified because lecithin-containing formulas show scarcely any adhesion to metal and can be removed en bloc from the metal parts of the extruder which are still hot after completion of the extrusion. The plasticity of the cooled melt is also beneficially affected so that deflashing of the tablets (removal of fins) takes place considerably better. [0031]
    • EXAMPLES 1 to 20
  • All the tests were carried out in a twin screw extruder (ZSK-40 extruder from Werner und Pfleiderer, Stuttgart). The extruder comprised 4 heatable sections, and it was possible to heat the extruder head and the slit die separately. The temperature settings are to be found in the table. The extruded melt was discharged in the form of a strip 12-14 cm wide through a slit die and subsequently directly compressed to tablets in a molding calender consisting of a pair of counter-rotating molding rolls (coolable). The tablets had an elongate, rod-like shape (oblong tablets without bar). The raw materials listed in the table have previously been mixed in a gyro-wheel mixer and fed as mixture into the extruder via a weigh feeder delivering 20 to 30 kg/h. The extruder conveyor was operated in all cases at 100 to 150 rpm. [0032]
  • For comparison purposes, formulations in which no lipid was used were processed. Although extrusion was possible in all these cases, calendering was not, because it was impossible to remove the tablets from the pairs of molding rolls in the calender. In addition, cleaning of the parts of the extruder coming into contact with the product was considerably more difficult in these cases (composition strongly adherent to metal surfaces) than with lipid-containing formulations. [0033]
    TABLE 1
    Ancillary
    Ex. Active ingredient Polymer substance Lipid Weight
    No. (a) (b) (c) (d) + (e) a:b:c:d:e T1 T2 T3 T4 TH TD
    1 Verapamil HCl HPC HPMC-100 Cast. 46/29/20/5/0 80 100 100 100 100 100
    2 Verapamil HCl HPC HPMC-100 Lec. 49/38/10/3/0 80 100 110 110 110 110
    3 Verapamil HCl HPC HPMC-4 Lec. 48/32/18/3/0 80 100 110 110 110 110
    4 Verapamil HCl HPC HPMC-4 Lec. 50/37/10/3/0 80 100 110 110 110 110
    5 Vcrapamil HCl HPC HPMC-100 Lec. + cast. 50/35/10/2.5/2.5 80 100 110 110 110 110
    6 Verapamil HCl HPC HPMC-100 Cast. 50/33/10/7/0 80 100 105 110 110 110
    7 Nifedipine HPC HPMC-100 Lec. 7.7/69.3/20/3/0 90 110 100 110 110 115
    8 Nifedipine HPC HPMC-100 Lec. 23.1/51.9/20/5/0 90 110 110 110 120 120
    9 Nifedipine HPC HPMC-100 Cast. 23.1/51.9/20/5/0 90 110 120 120 120 120
    10 1) HPC — — 20/80/0/0/0 140 140 140 140 140 130
    11 1) HPC — — 21.9/78.1/0/0/0 140 140 140 140 140 130
    12 Placebo HPC Mannitol — 0/60/40/0/0 90 120 100 100 120 120
    13 Placebo HPC — — 0/100/0/0/0 100 120 110 120 120 120
    14 1) HPC Mannitol Lec. 18.2/36.8/40/5/0 90 120 100 100 110 110
    15 Placebo HPC Mannitol Lec. 0/55/40/5/0 90 120 100 100 120 120
    16 1) HPC Mannitol Lec. 9/46/40/5/0 90 120 100 100 110 110
    17 2) HPC HPMC-100 — 10.4/49.6/40/0/0 130 110 110 110 110 115
    18 Placebo HPC HPMC-100 Lec. 0/58/40/2/0 90 110 100 110 110 110
    19 2) HPC HPMC-100 Lec. 19.8/38.2/40/2/0 90 105 95 105 105 110
    20 Placebo VA-64 Lactose Lec. 0/55/40/5/0 80 100 110 110 120 130

Claims (4)

We claim:
1. The use of lipids as aids in the production of solid drug forms by melt extrusion.
2. The use as claimed in
claim 1
, wherein phosphoglycerides are employed as lipids.
3. The use as claimed in
claim 2
, wherein lecithins are employed as lipids.
4. The use as claimed in any of
claims 1
 to
3
, wherein the lipids are employed in amounts of from 0.1 to 10% of the total weight of the drug forms.
US09/000,389 1995-08-25 1996-08-21 Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process Expired - Lifetime US6387401B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19531277A DE19531277A1 (en) 1995-08-25 1995-08-25 Use of lipids as an aid in the production of solid dosage forms by the melt extrusion process
DE19531277 1995-08-25
DE19531277.5 1995-08-25
PCT/EP1996/003667 WO1997007786A2 (en) 1995-08-25 1996-08-21 Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process

Publications (2)

Publication Number Publication Date
US20010007664A1 true US20010007664A1 (en) 2001-07-12
US6387401B2 US6387401B2 (en) 2002-05-14

Family

ID=7770352

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/000,389 Expired - Lifetime US6387401B2 (en) 1995-08-25 1996-08-21 Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process

Country Status (13)

Country Link
US (1) US6387401B2 (en)
EP (1) EP0845982B1 (en)
AR (1) AR003345A1 (en)
AT (1) ATE210970T1 (en)
AU (1) AU6875396A (en)
BR (1) BR9610234A (en)
CA (1) CA2227272C (en)
DE (2) DE19531277A1 (en)
DK (1) DK0845982T3 (en)
ES (1) ES2170259T3 (en)
HR (1) HRP960381A2 (en)
WO (1) WO1997007786A2 (en)
ZA (1) ZA967170B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105039A1 (en) * 2004-05-04 2005-11-10 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
US20090050262A1 (en) * 2005-02-17 2009-02-26 Jorg Rosenberg Production of Dosing Molds from Active Substance-Containing Melts
US20100119597A1 (en) * 1999-07-30 2010-05-13 Clarke Allan J Multi-component pharmaceutical dosage form

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532389A (en) * 1998-12-08 2002-10-02 ファレス ファーマシューティカル リサーチ エヌブイ Phospholipid composition
DE19916383A1 (en) * 1999-03-31 2000-10-05 Schering Ag Pharmaceutical composition with an extrusion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026699A1 (en) * 2000-05-30 2001-12-06 Basf Ag Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
TW200526274A (en) 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
AR048033A1 (en) * 2004-03-12 2006-03-22 Smithkline Beecham Plc PHARMACEUTICAL COMPOSITION TO MOLD COMPONENTS THAT INCLUDE COPOLIMERO OF POLY (MET) ACRYLATE, COVER, CONNECTOR OR SPACER OF CAPSULA MOLDED BY INJECTION THAT HAS THE PHARMACEUTICAL COMPOSITION AND FORM OF PHARMACEUTICAL MULTI-COMPONENT COMPONENTS
PL2200588T3 (en) * 2007-09-25 2019-09-30 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
JP2011503048A (en) 2007-11-08 2011-01-27 グラクソ グループ リミテッド Pharmaceutical formulation
CN102119026A (en) * 2008-06-13 2011-07-06 葛兰素集团有限公司 Hydroxypropyl cellulose capsule shell
CA2810837A1 (en) 2010-09-22 2012-03-29 Joseph R. Luber Manufacture of tablets from energy-applied powder blend
AT511581A1 (en) * 2011-05-26 2012-12-15 G L Pharma Gmbh ORAL RETARDANT FORMULATION
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
DE102017106216A1 (en) * 2017-03-22 2018-09-27 Amw Gmbh Extruded depot form for sustained release of active ingredient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581541B1 (en) * 1985-05-09 1988-05-20 Rhone Poulenc Sante NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF AN ACTIVE INGREDIENT AND THEIR PREPARATION METHOD
DE4226753A1 (en) 1992-08-13 1994-02-17 Basf Ag Preparations containing active substances in the form of solid particles
EP0744941B1 (en) * 1994-02-16 2003-06-04 Abbott Laboratories Process for preparing fine particle pharmaceutical formulations
DE4413350A1 (en) * 1994-04-18 1995-10-19 Basf Ag Retard matrix pellets and process for their production
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19504832A1 (en) * 1995-02-14 1996-08-22 Basf Ag Solid drug preparations

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100119597A1 (en) * 1999-07-30 2010-05-13 Clarke Allan J Multi-component pharmaceutical dosage form
US8440224B2 (en) 1999-07-30 2013-05-14 Capsugel Belgium Nv Multi-component pharmaceutical dosage form
WO2005105039A1 (en) * 2004-05-04 2005-11-10 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
US20070237823A1 (en) * 2004-05-04 2007-10-11 Thomas Bock Solid Pharmaceutical Form Comprising and Ltb4 Antagonist
JP2007536299A (en) * 2004-05-04 2007-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Solid pharmaceutical form containing LTB4 antagonite
US20090050262A1 (en) * 2005-02-17 2009-02-26 Jorg Rosenberg Production of Dosing Molds from Active Substance-Containing Melts

Also Published As

Publication number Publication date
DK0845982T3 (en) 2002-03-25
WO1997007786A3 (en) 1997-04-03
DE19531277A1 (en) 1997-02-27
AU6875396A (en) 1997-03-19
BR9610234A (en) 1999-06-29
AR003345A1 (en) 1998-07-08
EP0845982B1 (en) 2001-12-19
ATE210970T1 (en) 2002-01-15
CA2227272A1 (en) 1997-03-06
ZA967170B (en) 1998-03-02
US6387401B2 (en) 2002-05-14
WO1997007786A2 (en) 1997-03-06
HRP960381A2 (en) 1998-02-28
DE59608516D1 (en) 2002-01-31
ES2170259T3 (en) 2002-08-01
EP0845982A2 (en) 1998-06-10
CA2227272C (en) 2007-12-11

Similar Documents

Publication Publication Date Title
US6387401B2 (en) Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process
EP2258344B1 (en) Solid pharmaceutical dosage form comprising a ritonavir and lopinavir solid dispersion
EP0854707B1 (en) Solid medicaments obtained by extrusion of an isomalt-containing polymer-active substance melt
EP1162953B1 (en) Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances
US7413750B2 (en) Process for producing solid oral dosage forms with sustained release of active ingredient
EP1888040B1 (en) Pharmaceutical compositions comprising imatinib and a release retardant
KR100642976B1 (en) Tablets quickly disintegrating in the oral cavity and process for producing the same
AU2002238848B2 (en) Use of a spray-dried powder comprising a sugar alcohol
SK104397A3 (en) Solid active agent preparations
AU2007316558A1 (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP0864326A2 (en) Multiphasic preparation comprising an active agent
EP1107739B1 (en) Method for producing solid dosing forms
HU221614B (en) Transparent rapid-release preparations of non-steroid analgesics and process for producing them
KR20030042006A (en) Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same
DE19929361A1 (en) Mechanically stable pharmaceutical dosage forms containing liquid or semi-solid surface-active substances
KR102388870B1 (en) Use of amino sugars as plasticizers
AU702198B2 (en) The production of lenticular tablets by melt calendering
WO2004032903A2 (en) Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier
US6689299B2 (en) Process for producing solid creatine dosage forms and dosage forms obtainable thereby
GB2536519A (en) Method of preparing an extruded composition
JPS5879917A (en) Molding of glycine tablet
JPH11513696A (en) Method for producing solid drug
EP1479380B1 (en) Use of soaps such as magnesium stearate for increasing the release of drugs

Legal Events

Date Code Title Description
AS Assignment

Owner name: BASF AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROSENBERG, JOERG;BREITENBACH, JOERG;REEL/FRAME:009079/0898

Effective date: 19960909

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT GMBH & CO KG;REEL/FRAME:030688/0537

Effective date: 20121101

FPAY Fee payment

Year of fee payment: 12